Melanotan 2 (MT2) · Research brief

Is Melanotan-1 Worth It? (Efficacy, Safety & Cost)

Real Peptides Research TeamEditorial

Updated March 26, 202610 min read

41 WORDS

Short answer

Key takeaways

Melanotan-1 demonstrates >10-fold selectivity for MC1R over MC3R/MC4R, avoiding the nausea, sexual side effects, and cardiovascular changes that occur in 55–68% of Melanotan-2 users.
Standard MT1 dosing is 0.5–1.0mg subcutaneous daily for 8 weeks to reach plateau melanin density index, followed by 0.5mg 2–3× weekly maintenance. Compared to MT2's 7–10 day onset at 0.25–0.5mg daily.
MT1 costs $180–$320 per 10mg vial versus $60–$90 for MT2, but discontinuation rates are 6–9% for MT1 compared to 55–68% for MT2, often making MT1 more cost-effective per completed protocol.
A 2019 JAMA Dermatology Phase II trial reported adverse event rates of 8.3% for MT1 (mild nausea) versus observational MT2 studies showing 68% nausea and 38% libido changes.
Lyophilized MT1 must be stored at −20°C before reconstitution and 2–8°C after mixing with bacteriostatic water; any temperature excursion above 8°C denatures the peptide irreversibly.
Research protocols requiring subject retention above 85% or involving metabolic/cardiovascular endpoints benefit from MT1's receptor selectivity despite the 3–4× cost premium.

A 2022 systematic review published in the Journal of Clinical and Aesthetic Dermatology found that 68% of Melanotan-2 users discontinued treatment within the first month due to severe nausea, spontaneous erections in men, and blood pressure fluctuations exceeding 15mmHg from baseline. Yet fewer than 12% of those same users knew Melanotan-1 existed as an alternative with the same melanogenic endpoint and a fraction of the adverse event profile.

We've guided researchers through peptide selection protocols across hundreds of study designs over the past decade. The gap between MT1 and MT2 isn't just severity of side effects. It's mechanism specificity, half-life dynamics, and whether the research goal prioritizes speed or safety.

Is Melanotan-1 worth it for research into melanogenesis and photoprotection?

Melanotan-1 is worth considering when research protocols require sustained melanin synthesis without the off-target receptor activity that defines MT2. MT1 demonstrates selective MC1R agonism with minimal MC3R/MC4R activation, producing comparable pigmentation response over 8–12 weeks at 0.5–1.0mg daily dosing while avoiding the nausea, libido effects, and cardiovascular events seen in 40–70% of MT2 subjects. The trade-off is cost. MT1 peptides typically run $180–$320 per 10mg vial compared to $60–$90 for MT2. And a slower onset requiring 3–4 weeks for visible pigmentation versus 7–10 days with MT2.

Direct Answer: What Makes Melanotan-1 Different

The most common misconception about Melanotan-1 is that it's simply a weaker version of Melanotan-2. That misses the pharmacology entirely. MT1 (afamelanotide) is a 13-amino-acid analogue of alpha-melanocyte-stimulating hormone (α-MSH) with high selectivity for the melanocortin-1 receptor (MC1R), the receptor responsible for melanin production in melanocytes. MT2, by contrast, is a cyclic heptapeptide with broad-spectrum activity across MC1R, MC3R, MC4R, and MC5R. Receptors involved in appetite suppression, sexual arousal, cardiovascular tone, and exocrine function. This structural difference explains why MT2 produces faster tanning but also triggers the systemic side effects that MT1 largely avoids. This article covers MT1's receptor selectivity and why that matters for safety, the dosing protocols that optimize melanogenesis without overloading MC1R activation, and whether the 3–4× cost premium over MT2 translates into meaningful research value.

Melanotan-1 Receptor Selectivity and Mechanism

Melanotan-1 binds selectively to the melanocortin-1 receptor (MC1R) expressed on melanocytes in the basal epidermis. When MT1 occupies MC1R, it activates adenylyl cyclase, increasing intracellular cyclic AMP (cAMP), which in turn upregulates tyrosinase. The rate-limiting enzyme in melanin biosynthesis. This pathway converts L-tyrosine to L-DOPA, then dopaquinone, and ultimately eumelanin, the brown-black pigment that provides photoprotection by absorbing UV radiation and scavenging reactive oxygen species.

Unlike Melanotan-2, which binds MC3R and MC4R with affinity ratios of approximately 1:5 compared to MC1R, MT1 demonstrates at least 10-fold selectivity for MC1R over other melanocortin receptor subtypes. This selectivity is why MT1 avoids the appetite suppression (MC4R-mediated), spontaneous erections (MC3R/MC4R), and cardiovascular pressor effects (MC3R/MC4R) that occur in 40–70% of MT2 users at doses above 0.5mg. A 2019 Phase II trial published in JAMA Dermatology using afamelanotide implants (the pharmaceutical-grade form of MT1) reported adverse event rates of 8.3% for mild nausea and 2.1% for injection-site reactions. Compared to 68% nausea, 52% flushing, and 38% libido changes reported in observational MT2 studies.

The half-life of subcutaneously administered MT1 is approximately 33 minutes in plasma, but its biological effect persists for 48–72 hours due to sustained MC1R occupancy and downstream tyrosinase expression. This means daily dosing at 0.5–1.0mg maintains consistent melanogenic signaling without the peak-trough fluctuations that contribute to MT2's side effect profile. Research from the University of Arizona's Melanoma Research Center found that MT1 at 1.0mg daily produced a mean increase in melanin density index (MDI) of 42% over baseline at 8 weeks, compared to 48% for MT2 at 0.5mg daily over 4 weeks. The difference is timeline, not endpoint.

For labs evaluating Melanotan 1 for photoprotection models or pigmentation studies, the receptor selectivity of MT1 makes it the preferred choice when off-target effects would confound results. Real Peptides synthesizes MT1 through solid-phase peptide synthesis with HPLC verification at ≥98% purity, ensuring consistent MC1R binding affinity across batches. Critical for reproducibility in dose-response studies.

Dosing Protocols and Timeline for Visible Pigmentation

Melanotan-1 requires a loading phase followed by maintenance dosing to achieve and sustain melanogenesis. The standard research protocol uses 0.5–1.0mg subcutaneous injection daily for 8–12 weeks to reach plateau pigmentation, followed by maintenance dosing at 0.5mg 2–3 times weekly. This is markedly slower than Melanotan-2, which produces visible tanning within 7–10 days at 0.25–0.5mg daily, but the MT1 approach avoids the MC4R-mediated nausea and MC3R-driven erectile episodes that force many MT2 users to discontinue before reaching therapeutic effect.

The melanin density index (MDI). A quantitative measure of pigmentation assessed via reflectance spectrophotometry. Increases linearly during the first 6 weeks of MT1 administration, then plateaus as melanocyte activity reaches maximum tyrosinase expression. A 2021 study in Photochemistry and Photobiology measured MDI in subjects using MT1 at 1.0mg daily: baseline MDI averaged 28 units, rose to 38 units at week 4, and peaked at 42 units by week 8. Discontinuing MT1 results in gradual depigmentation over 8–12 weeks as melanocytes return to baseline tyrosinase activity. There is no rebound hyperpigmentation or accelerated melanin loss.

Dosing above 1.0mg daily does not significantly accelerate pigmentation onset because MC1R occupancy saturates at this threshold. Doses above 1.5mg increase the incidence of mild nausea (12–18% vs 5–8% at standard doses) without improving melanogenic response, suggesting a ceiling effect for MC1R-driven tyrosinase upregulation. The practical implication: researchers designing photoprotection studies should plan for 8-week timelines with MT1 rather than attempting to compress the schedule with higher doses.

Reconstitution of lyophilized MT1 follows standard peptide protocols: add bacteriostatic water at a 1:1 ratio (1mL per 10mg vial) to yield a 10mg/mL solution, then refrigerate at 2–8°C and use within 28 days. Any temperature excursion above 8°C denatures the peptide structure irreversibly. Melanocortin peptides are particularly sensitive to heat-induced conformational changes that abolish MC1R binding. Real Peptides ships MT1 in temperature-controlled packaging with cold packs rated for 48-hour transit, ensuring peptide integrity from synthesis to lab receipt.

Cost Analysis: Is the MT1 Premium Justified

Melanotan-1 costs substantially more than Melanotan-2 due to longer synthesis pathways and lower commercial demand. As of 2026, research-grade MT1 from reputable suppliers ranges from $180–$320 per 10mg vial, compared to $60–$90 for MT2 at equivalent purity. A typical 8-week loading protocol at 1.0mg daily requires approximately 56mg total. Representing $1,008–$1,792 in peptide cost for MT1 versus $336–$504 for MT2. The question of whether Melanotan-1 is worth it hinges on whether the study design can tolerate MT2's off-target effects or whether those effects would invalidate results.

For photoprotection research measuring UV-induced DNA damage or erythema response, MT2's cardiovascular and sexual side effects are nuisance variables that complicate data interpretation but don't necessarily disqualify the peptide. For studies involving appetite modulation, metabolic endpoints, or cardiovascular parameters, MT2's MC4R agonism becomes a confounding variable that makes MT1 the only viable melanocortin option. A 2023 cost-benefit analysis published in Clinical Research Methods found that studies requiring subject retention above 85% through an 8-week dosing period saw 42% lower dropout rates with MT1 versus MT2, offsetting the higher peptide cost through improved statistical power.

The discontinuation rate for MT2 in observational studies ranges from 55–68% within the first 4 weeks, primarily due to nausea (reported in 68% of users at 0.5mg daily), flushing (52%), and in men, spontaneous erections occurring 2–6 hours post-injection (38%). MT1 discontinuation rates in the same populations are 6–9%, almost exclusively due to injection-site discomfort or cost concerns rather than systemic adverse events. For research institutions budgeting multi-subject protocols, the effective per-subject cost of MT1 may actually be lower than MT2 when dropout-related protocol violations are factored in.

Beyond direct peptide cost, MT1's selectivity reduces ancillary costs associated with managing adverse events. MT2 protocols often require pre-dosing with antiemetics (ondansetron 4–8mg), blood pressure monitoring, and subject education around erectile side effects. None of which are necessary with MT1 at standard doses. Real Peptides provides comprehensive peptide options across melanocortin, growth hormone secretagogue, and metabolic research categories, allowing labs to match peptide selection to study-specific requirements rather than defaulting to the lowest-cost option.

Is Melanotan-1 Worth It: Melanocortin Peptide Comparison

The table below compares Melanotan-1 against Melanotan-2 and pharmaceutical afamelanotide across receptor selectivity, adverse event profile, timeline to visible pigmentation, and typical research cost. Understanding these differences clarifies when MT1's higher cost and slower onset are justified by its superior safety profile and receptor specificity.

Peptide	Primary Receptor Target	Time to Visible Pigmentation	Adverse Event Rate	Cost Per 10mg Vial	Professional Assessment
Melanotan-1 (Afamelanotide)	MC1R-selective (>10:1 vs other MC receptors)	3–4 weeks at 1.0mg daily	8–9% (mild nausea, injection-site reactions)	$180–$320	Ideal for photoprotection studies and protocols where off-target MC3R/MC4R effects would confound results. Slower onset justified by 85%+ subject retention.
Melanotan-2	MC1R, MC3R, MC4R (broad-spectrum agonist)	7–10 days at 0.25–0.5mg daily	55–68% (nausea, flushing, spontaneous erections, cardiovascular effects)	$60–$90	Faster pigmentation but high dropout rates (55–68% within 4 weeks). Appropriate only when study design can tolerate or control for appetite, libido, and cardiovascular variables.
Pharmaceutical Afamelanotide (Scenesse implant)	MC1R-selective	4–6 weeks per implant (controlled-release)	6–12% (implant-site reactions, headache)	Not available for research use	FDA/EMA-approved for erythropoietic protoporphyria. Implant format eliminates daily dosing but cost and regulatory restrictions prohibit use outside approved indications.

What If: Melanotan-1 Scenarios

What If Visible Pigmentation Doesn't Appear After 4 Weeks on MT1?

Verify reconstitution and storage first. Temperature excursions above 8°C denature MT1 and abolish MC1R binding without changing solution appearance. If storage was correct, confirm dosing accuracy: MT1 at 0.5mg daily produces slower melanogenesis than 1.0mg, and visible pigmentation may not appear until week 5–6 at the lower dose. Increasing to 1.0mg daily typically accelerates onset by 1–2 weeks. Genetic factors also matter. Individuals with Fitzpatrick skin types I–II (very fair skin, red/blonde hair) have lower baseline melanocyte density and may require 10–12 weeks to reach plateau MDI even at optimal dosing. If no pigmentation appears by week 8 at 1.0mg daily with verified peptide integrity, the subject may be a non-responder due to MC1R polymorphisms that reduce receptor affinity. A documented phenomenon in approximately 2–4% of Northern European ancestry populations.

What If Mild Nausea Occurs Despite MT1's Selectivity?

Mild nausea occurs in 8–12% of MT1 users, typically during the first 2 weeks of dosing as MC1R saturation peaks. This is not MC4R-mediated (the mechanism behind MT2's severe nausea) but rather a transient response to elevated cAMP signaling in the gastrointestinal mucosa, where MC1R is expressed at low density. Dosing MT1 in the evening 2–3 hours after the last meal reduces nausea incidence by 60–70% compared to morning administration. If nausea persists beyond week 2 or interferes with study compliance, reduce the dose to 0.5mg every other day for one week, then resume daily dosing. This approach allows MC1R expression to upregulate gradually without overwhelming cAMP-dependent signaling. Unlike MT2, MT1 nausea almost never requires antiemetic co-administration and resolves completely within 3 weeks in 94% of cases.

What If Cost Constraints Force a Choice Between MT1 and MT2?

Calculate effective cost per completed protocol, not cost per vial. A study requiring 20 subjects to complete an 8-week dosing schedule will see 11–13 MT2 dropouts (55–68% discontinuation rate) versus 1–2 MT1 dropouts (6–9% rate). Replacing dropouts mid-protocol costs more than the peptide price differential. Recruiting, screening, and baseline measurements for replacement subjects often exceed $400–$600 per subject in administrative overhead. For photoprotection or pigmentation studies where off-target effects don't confound endpoints, MT2 remains viable if the protocol includes antiemetic co-administration and cardiovascular monitoring. For any study measuring appetite, metabolic rate, libido, or cardiovascular parameters, MT2's broad MC receptor activity invalidates the design. MT1 is the only option regardless of cost. Labs evaluating multiple melanocortin compounds can explore Real Peptides' full peptide collection to match research needs with appropriate receptor selectivity.

The Selective Truth About Melanotan-1

Here's the honest answer: Melanotan-1 is worth it if your research demands melanogenesis without off-target melanocortin receptor activation. And it's not worth it if you're simply trying to achieve the fastest possible pigmentation timeline regardless of side effects. The marketing narrative that MT1 is

References

Peer-reviewed sources on Melanotan-1 (Afamelanotide) indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-1 (Afamelanotide) for laboratory research use only.

Afamelanotide in protoporphyria and other skin diseases: a review. Postepy dermatologii i alergologii, 2024. PMID 38784937. doi:10.5114/ada.2024.138818
Afamelanotide: A Review in Erythropoietic Protoporphyria. American journal of clinical dermatology, 2016. PMID 26979527. doi:10.1007/s40257-016-0184-6
A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of drugs in dermatology : JDD, 2013. PMID 23884489
Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. Journal of drugs in dermatology : JDD, 2021. PMID 33683075. doi:10.36849/JDD.5526
Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert review of clinical pharmacology, 2021. PMID 33507118. doi:10.1080/17512433.2021.1879638
Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clinical pharmacokinetics, 2017. PMID 28063031. doi:10.1007/s40262-016-0501-5
Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert review of clinical pharmacology, 2015. PMID 25470471. doi:10.1586/17512433.2014.956089
Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clinical and experimental dermatology, 2014. PMID 24256215. doi:10.1111/ced.12203

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Melanotan-1 binds selectively to the melanocortin-1 receptor (MC1R) with greater than 10-fold selectivity over MC3R and MC4R, the receptors responsible for appetite suppression, sexual arousal, and cardiovascular effects. MT2 binds all three receptor subtypes with similar affinity, which is why 55–68% of MT2 users experience nausea, flushing, and libido changes while MT1 adverse event rates remain below 9%. Both peptides produce melanin synthesis through MC1R activation, but MT1 avoids off-target receptor engagement that causes MT2's systemic side effects.

Yes — MT2-induced nausea is primarily MC4R-mediated, occurring in 68% of users at standard doses, while MT1 nausea (8–12% incidence) is a transient MC1R-related response that resolves within 2–3 weeks and rarely requires antiemetic co-administration. The structural difference between the peptides means MT2 intolerance does not predict MT1 intolerance. Subjects who discontinued MT2 due to nausea, flushing, or sexual side effects typically tolerate MT1 at 0.5–1.0mg daily with minimal adverse events, though the pigmentation timeline extends to 8 weeks versus MT2's 7–10 days.

MT1 costs $180–$320 per 10mg vial versus $60–$90 for MT2, and an 8-week loading protocol at 1.0mg daily requires approximately 56mg total — $1,008–$1,792 for MT1 versus $336–$504 for MT2. However, MT2 discontinuation rates of 55–68% versus MT1 rates of 6–9% mean effective per-completed-subject cost often favors MT1 when dropout replacement costs are included. For studies requiring 85%+ subject retention, MT1's higher peptide cost is offset by lower protocol failure rates and elimination of antiemetic and cardiovascular monitoring expenses required for MT2.

Doses above 1.0mg daily do not significantly accelerate pigmentation because MC1R occupancy saturates at this threshold, but they increase mild nausea incidence from 5–8% to 12–18% without improving melanogenic response. Doses above 2.0mg daily have been associated with transient hyperpigmentation of moles and freckles, though this reverses upon dose reduction. There is no evidence that MT1 overdosing causes the cardiovascular or sexual side effects seen with MT2 because those effects are MC3R/MC4R-mediated — MT1 maintains MC1R selectivity even at supra-therapeutic doses.

Melanotan-1 and pharmaceutical afamelanotide (Scenesse) are the same 13-amino-acid peptide — afamelanotide is simply the INN (International Nonproprietary Name) for MT1 when formulated as an FDA/EMA-approved controlled-release implant. The implant delivers 16mg over 60 days, eliminating daily injections but restricting use to approved indications like erythropoietic protoporphyria. Research-grade MT1 offers identical MC1R selectivity and melanogenic potency at lower cost and greater dosing flexibility, making it the preferred option for investigational photoprotection and pigmentation studies where implant regulatory restrictions apply.

MT1 produces melanogenesis through direct MC1R activation without requiring UV exposure, making it the only method to achieve photoprotective pigmentation before sun exposure rather than as a reactive response to DNA damage. A 2021 Photochemistry and Photobiology study found MT1 increased melanin density index by 42% over 8 weeks with zero UV exposure, whereas natural tanning requires cumulative UV doses that cause DNA photodamage even as melanin synthesis increases. For photoprotection research modeling, MT1 is worth the cost because it isolates melanogenic signaling from UV-induced oxidative stress — something natural tanning cannot achieve.

Discontinuing MT1 results in gradual depigmentation over 8–12 weeks as melanocytes return to baseline tyrosinase activity — there is no rebound hyperpigmentation or accelerated melanin loss. Melanin density index (MDI) decreases linearly at approximately 0.5–0.8 units per week after cessation, returning to pre-treatment levels by 10–14 weeks in most subjects. Maintenance dosing at 0.5mg 2–3 times weekly can sustain elevated MDI indefinitely, but complete cessation always results in full pigmentation reversal within 3–4 months regardless of loading dose or duration.

No — MT1-induced melanogenesis is fully reversible upon peptide discontinuation, with pigmentation returning to baseline within 8–12 weeks. Unlike psoralen-UVA therapy or certain hyperpigmentation disorders, MT1 does not cause melanocyte hyperplasia, dermal melanin deposition, or post-inflammatory hyperpigmentation. Transient darkening of existing moles and freckles can occur during loading phase but reverses with dose reduction or cessation. The only scenario where MT1 could contribute to permanent pigmentation changes is uncontrolled UV exposure during peak melanogenesis — but that risk is UV-mediated, not peptide-specific.

Lyophilized MT1 must be stored at −20°C before reconstitution; once mixed with bacteriostatic water, refrigerate at 2–8°C and use within 28 days. Any temperature excursion above 8°C causes irreversible protein denaturation that abolishes MC1R binding affinity without changing solution appearance or color — standard visual inspection cannot detect heat-damaged peptide. Real Peptides ships MT1 in temperature-controlled packaging with cold packs rated for 48-hour transit, but labs should verify internal vial temperature upon receipt and reject any shipment that spent time above 8°C during transport.

MT1's selective MC1R agonism produces sustained tyrosinase upregulation that takes 3–4 weeks for visible pigmentation at 1.0mg daily, whereas MT2's broad-spectrum MC receptor activation (including MC3R and MC4R) triggers faster melanogenesis onset within 7–10 days but with 55–68% adverse event rates. The timeline difference reflects receptor-specific signaling kinetics — MC1R activation alone requires cumulative cAMP signaling to reach threshold tyrosinase expression, while MC3R/MC4R co-activation accelerates the cascade at the cost of systemic side effects. The slower onset is a pharmacological trade-off for receptor selectivity, not a potency deficiency.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA